钆布醇的临床安全性:超过25年使用经验及逾1亿次给药的综述
本文综述了钆布醇自1998年2月上市至2022年12月31日的安全性数据,包括45项II-IV期临床研究(7856例患者)和上市后监测。药物相关不良事件报告率为3.4%,严重不良事件<0.1%;上市后监测总报告率0.0356%。在获批适应证和人群中获益-风险特征良好。
要点
- 药物相关不良事件3.4%,严重不良事件<0.1%,恶心(0.7%)和味觉障碍(0.4%)最常见。
- 上市后监测总报告率0.0356%,超敏反应0.0147%,恶心0.0032%,呕吐0.0025%,呼吸困难0.0010%。
- 儿童研究(7292例)不良事件报告率0.84%(61例),其中严重3例;≥65岁患者不良事件显著少于年轻患者。
核心结论
- 全球超过1亿次给药显示钆布醇在获批适应证和人群中获益-风险特征良好。
研究设计与样本
- 对1998年2月至2022年12月31日的II-IV期临床研究和上市后监测安全性数据进行描述性分析,并批判性总结特殊风险人群文献;45项II-IV期研究纳入7856例接受钆布醇的患者。
诊断标准与关键数值
- II-IV期研究中药物相关不良事件报告率3.4%,严重不良事件<0.1%,恶心0.7%,味觉障碍0.4%,其余药物相关不良事件≤0.3%。
- 上市后监测(含临床试验)总药物不良反应报告率0.0356%,超敏反应0.0147%,恶心0.0032%,呕吐0.0025%,呼吸困难0.0010%,其余均<0.001%。
- 儿童研究(7292例≤18岁,其中112例<2岁)报告61例药物不良反应(0.84%),含3例严重不良反应。
- 共收到4份诊断或符合肾源性系统性纤维化的报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The macrocyclic gadolinium-based contrast agent gadobutrol was introduced to the market in February 1998. Over the last 25 years, gadobutrol has been administered more than 100 million times worldwide providing a wealth of data related to safety.
OBJECTIVE: The aim of this study was to perform a thorough review and status update on gadobutrol's safety.
MATERIALS AND METHODS: Safety data from the clinical phase II-IV program and postmarketing surveillance were descriptively analyzed from February 1998 until December 31, 2022. Literature on special at-risk populations and specific safety aspects was critically summarized.
RESULTS: Forty-five clinical phase II-IV studies recruited 7856 patients receiving gadobutrol. Drug-related adverse events (AEs) were reported in 3.4% and serious AEs in <0.1% of patients. Nausea (0.7%) and dysgeusia (0.4%) were the most reported AEs. All other drug-related AEs occurred ≤0.3%. After more than 100 million gadobutrol administrations, overall adverse drug reactions (ADRs) from postmarketing surveillance (including clinical trials) were rare with an overall reporting rate of 0.0356%, hypersensitivity reactions (0.0147%), nausea (0.0032%), vomiting (0.0025%), and dyspnea (0.0010%). All other ADRs were <0.001%. No trend for higher rates of AEs was found in patients with reduced renal or liver function. Seven clinical studies reported safety findings in 7292 children ≤18 years, thereof 112 newborns/toddlers younger than 2 years. Overall, 61 ADRs (0.84%) were reported, including 3 serious ones. Adverse events in patients ≥65 years of age ("elderly") were significantly less frequent than in younger patients. A total of 4 reports diagnostic of or consistent with nephrogenic systemic fibrosis have been received. No causal relationship has been established between clinical signs and symptoms and the presence of small amounts of gadolinium in the body in patients with normal renal function after use of gadobutrol.
CONCLUSIONS: More than 100 million administrations worldwide have shown gadobutrol's well-established benefit-risk profile in any approved indication and populations.
引用
- Endrikat J, Gutberlet M, Hoffmann KT, et al. Clinical Safety of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations. Invest Radiol. 2024. PMID: 38426761. doi:10.1097/RLI.0000000000001072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。